Transoma Medical, Inc. Postpones Initial Public Offering (IPO) Due to Market Conditions

ST. PAUL, Minn.--(BUSINESS WIRE)--Transoma Medical, Inc., announced this morning that it is postponing its initial public offering due to unfavorable market conditions. Transoma expects to proceed with the IPO at a future date and will evaluate market conditions to determine the appropriate timing.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification of the securities under the securities laws of that state.
A copy of the preliminary prospectus related to the offering may be obtained by contacting Piper Jaffray & Co., U.S. Bancorp Center, 800 Nicollet Mall, Minneapolis, Minnesota 55402.
About Transoma Medical, Inc.
Transoma Medical, Inc., headquartered in St. Paul, Minnesota, is a medical technology company engaged in developing, manufacturing and distributing implantable, subcutaneous, wireless diagnostic and monitoring products. Transoma is focused on two distinct markets - the chronic cardiovascular disease (CVD) market, through its Patient Management Device (PMD) division, and the biomedical research market, through its Data Sciences International (DSI) division.
Transoma’s PMD division is focused on developing implantable, ambulatory monitoring systems that provide physicians with vital signs information that is important to accurately diagnose various forms of CVD, and to optimize drug, interventional, surgical and device treatment alternatives. Transoma’s DSI division is the leading supplier of wireless, physiologic monitoring equipment and a significant supplier of related data acquisition and analysis products used in biomedical research, including in preclinical drug discovery and development.